{"id":"W2107806473","doi":"10.1016/j.eururo.2012.10.048","title":"Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder","year":2012,"lang":"en","type":"article","venue":"European Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Astellas Pharma Canada; Pfizer; Eli Lilly and Company","keywords":"Mirabegron; Tolterodine; Medicine; Overactive bladder; Tolerability; Placebo; Urology; Adverse effect; Internal medicine; Discontinuation; Agonist; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06821404398549276,"score_gpt":0.3772788177020855,"score_spread":0.3090647737165927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}